Testing a new medication for a rare blood disorder with a specific genetic mutation

This trial is testing a medication called enasidenib to treat a rare blood disorder called myelodysplastic syndrome (MDS) in patients whose cancer cells have a specific genetic mutation (IDH2). Some patients will receive enasidenib alone, while others will receive it combined with another medication called azacitidine. Researchers want to understand if this treatment is safe and whether it can help control the disease.

Patients with MDS and this specific genetic mutation have limited treatment options and often develop into more serious blood cancers. This trial exists to test whether targeting this particular genetic change with the medication could offer patients a new, more effective way to fight their disease.